Monday, November 2, 2026

Pfizer Stock Is 2.67% Up So Far On Wednesday

ViaNews Editorial Team

December 2, 2020

Pfizer Stock Is 2.67% Up So Far On Wednesday

Shares of Pfizer rose 2.67% to $40.46 at 11:12 EST on Wednesday, after three sequential sessions in a row of gains. The New York Stock Exchange is dropping 0.07% to $14,137.00, following yesterday's upward trend, on what up until now seems, a somewhat negative trend trading session today.

Pfizer's last close was $39.41, 0.10% under its 52-week high of $40.50.

News about Pfizer today

Pfizer-biontech coronavirs vaccine gains approval for use in the UK. According to today's article on ForexLive, "UK says that the vaccine will be made available starting from next week This has been widely anticipated but it adds to the optimism and buzz surrounding vaccine developments."

Pfizer says US FDA and EU EMA decisions on authorisation expected this month as well. According to today's article on ForexLive, "Pfizer briefs after the UK MHRA authorises emergency-use supply for its coronavirus vaccine The pharmaceutical firm also confirms that companies are ready to deliver the first doses to the UK immediately."

According to today's article on MarketWatch, "U.K"

Pfizer, biontech's covid-19 vaccine wins u.k. authorization. According to today's article on The Wall Street Journal, "Britain became the first Western nation to grant emergency-use authorization for a Covid-19 vaccine, clearing a shot developed by Pfizer and Germany’s BioNTech to be distributed in limited numbers within days.."

Salesforce.com, Pfizer, biontech: what to watch when the stock market opens today. According to today's article on The Wall Street Journal, "U.S"

Pfizer's Sales

Pfizer's sales growth is a negative 9.7% for the ongoing quarter and a decline by 9.1% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 12.7% and a negative 12.5%, respectively.

Pfizer's Revenue

Year-on-year quarterly revenue growth declined by 4.3%, now sitting on 48.65B for the twelve trailing months.

Pfizer's Stock Top and Bottom Yearly Value

Pfizer's stock is valued at $40.46 at 11:12 EST, under its 52-week high of $40.50 and way higher than its 52-week low of $26.45.

Pfizer's Moving Average

Pfizer's worth is way higher than its 50-day moving average of $35.66 and way higher than its 200-day moving average of $34.81.

Previous days news about Pfizer

According to yesterday's article on Bloomberg Quint, "Pfizer, BioNTech Seek Clearance to Sell Covid Vaccine in Europe."

Pfizer, biontech seek EU clearance for covid-19 vaccine. According to yesterday's article on Bloomberg Quint, "Pfizer Inc"

Pfizer-biontech seeks EU clearance for coronavirus vaccine. According to yesterday's article on ForexLive, "Pfizer vaccine can be in use in the EU by the year-end if cleared Pfizer-BioNTech just announced that they have submitted an application to the EMA today to seek clearance for coronavirus vaccine use in the EU.."

Pfizer, biontech file for covid-19 vaccine approval in europe. According to yesterday's article on The Wall Street Journal, "Pfizer and partner BioNTech said they are seeking approval from the European Union for their coronavirus vaccine.."

Pfizer, biontech apply for CMA in europe for covid-19 vaccine candidate. According to yesterday's article on MarketWatch, "Shares of Pfizer Inc"

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Goes Operational: Platform Governance, Local Silicon, and the Physical-AI Data Race
In mid-to-late October 2026, enterprise vendors (Cisco, Fortinet, ServiceNow, Intuit, Salesforce/Braze, Adobe) shipped agent governance, AI security and AI-driven customer engagement products, while a parallel hardware wave (NVIDIA RTX Spark laptops, ASUS, Apple's iPad mini, Microsoft's hybrid local/cloud Windows) pushed AI onto local devices. A third strand, physical AI (Encord, Harvest Praxis, Hesai), argues that real-world sensor data and cheaper edge chips are the next bottleneck. The common thread is the shift from AI experimentation to governed, scaled deployment, with Salesforce's Braze acquisition showing consolidation and fintech players like Intuit tying AI to trusted financial data. The facts support a broad industry theme but contain little direct finance or regulatory evidence, so the AI-finance angle is thin.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,533 source documents archived
Query this data → isubstrate.com